StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie eye Care Portfolio [folded into All Other in Q1 2026] — U.S. reported growth YoY (%) (%)

Form 8-K Key Product Revenues Schedule

Latest, Q4 2025
-19.7%
Period ended Dec 31, 2025
Change on a year earlier
-32.5 pts
12.8% in Q4 2024
History
18 quarters
Since Q3 2021
Sources
18
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEye Care Portfolio [folded into All Other in Q1 2026] — U.S. reported growth YoY (%) (%)Year on yearSource
Q4 2025Dec 31, 2025-19.7%-32.5 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025-8.0%+14.9 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025-5.7%+16.1 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 2025-2.6%+26.6 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202412.8%+19.7 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 2024-22.9%-8.9 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024-21.8%+2.3 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024-29.2%+6.5 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 2023-6.9%+42.8 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023-14.0%+24.1 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023-24.1%+10.0 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 2023-35.7%-29.4 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-49.7%-57.3 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 2022-38.1%-44.6 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗
Q2 2022Jun 30, 2022-34.1%–Form 8-K (abbv-20220630xexhibit991.htm, filed 2022-07-29) ↗
Q1 2022Mar 31, 2022-6.3%–Form 8-K (abbv-20220331xexhibit991.htm, filed 2022-04-29) ↗

Cite this data

StockData. (2026). AbbVie Eye Care Portfolio [folded into All Other in Q1 2026] — U.S. reported growth YoY (%) (%), quarterly Q3 2021–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta_eye_us_rep_yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.